SlideShare una empresa de Scribd logo
1 de 20
Descargar para leer sin conexión
A Seminar On
ICH GUIDELINES
Presented By
SAURABH R. SOJITRA
M.Pharm. I (Pharmaceutics)
Under The Guidance Of
Prof. Ms. H. R. HINGLAJIA
CONTENT
Introduction
Aim
ICH Parties
Objectives
Topic Of ICH
Overview Of ICH
Reference
INTRODUCTION
The International Conference on
Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human
Use (ICH) is a unique project that brings
together the regulatory authorities of Europe,
Japan and the United States and experts from
the pharmaceutical industry in the three
regions to discuss scientific and technical
aspects of product registration.
AIM
The International Conference on Harmonisation of Technical
Requirements for the Registration of Pharmaceuticals for
Human Use (ICH) was established in 1990 as a joint
regulatory/industry project to improve, through
harmonisation, the efficiency of the process for developing
and registering new medicinal products in Europe, Japan
and the United States, in order to make these products
available to patients with a minimum of delay.
The six parties to ICH represent the regulatory bodies and
research based industry in the three regions, Europe, Japan
and the USA, where the vast majority of new medicines are
currently developed.
ICH PARTIES
European Commission European Union (EU)
European Federation of Pharmaceutical Industries and
Associations (EFPIA)
Ministry of Health, Labour and Welfare, Japan (MHLW)
Japan Pharmaceutical Manufacturers Association (JPMA)
US Food and Drug Administration (FDA)
Pharmaceutical Research and Manufacturers of America
(PhRMA)
OBJECTIVES
More economical use of human, animal, and
material resources
Elimination of unnecessary delay in the
global development & availability of new
medicines.
Maintaining safeguards on Quality, safety,
efficacy and regulatory obligations to protect
public health.
TOPIC OF ICH
Four Broad Categories - QSEM
Quality (Q): those relating to chemical and pharmaceutical Quality
Assurance (Stability Testing, Impurity Testing, etc.)
Safety (S): those relating to in vitro and in vivo pre-clinical studies
(Carcinogenicity Testing, Genotoxicity Testing, etc.)
Efficacy (E): those relating to clinical studies in human subject (Dose
Response Studies, Good Clinical Practices, etc.)
Multidisciplinary (M): cross-cutting Topics which do not fit uniquely
into one of the above categories (MedDRA, ESTRI, M3, CTD, M5)
OVERVIEW OF ICH
1. QUALITY
Q1A (R2): STABILITY TESTING OF NEW DRUGS
AND PRODUCTS
QIB: PHOTOSTABILITY TESTING
Q1C: STABILITY TESTING OF NEW DOSAGE
FORMS
Q1D: BRACKETING AND MATRIXING DESIGNS
FOR STABILITY TESTING OF DRUG
SUBSTANCES AND DRUG PRODUCTS.
Q1E: EVALUATION OF STABILITY DATA
QIF: STABILITY DATA PACKAGE FOR
REGISTRATION IN CLIMATIC ZONES III AND IV
Q2A: DEFINITIONS AND TERMINOLOGY:
ANALYTICAL VALIDATION
Q2B: METHODOLOGY
03A(R2) IMPURITIES IN NEW DRUG
SUBSTANCES
03B(R2): IMPURITIES IN NEW DRUG PRODUCT
03C(R3) IMPURITIES GUIDELINES FOR
RESIDUAL SOLVENTS
Q4: PHARMACOPOEIA
Q4A: PHARMACOPOEIAL
HARMONIZATION
Q5A: VIRAL SAFETY EVALUATION
Q5B: GENETIC STABILITY
Q5C: STABILITY OF BIOTECHNOLOGY
PRODUCTS
Q5D: CELL SUBSTRATES
Q6A: SPECIFICATIONS, TEST PROCEDURES AND
ACCEPTANCE CRITERIA FOR NEW DRUG
SUBSTANCES AND PRODUCTS
Q6B : SPECIFICATIONS TEST PROCEDURES AND
ACCEPTANCE CRITERIA FOR
BIOTECHNOLOGICAL/ BIOLOGICAL PRODUCTS
Q7A: GMP FOR ACTIVE PHARMACEUTICAL
INGREDIENTS
Q8: PHARMACEUTICAL DEVELOPMENT
Q9: QUALITY RISK MANAGEMENT
Q10: PHARMACEUTICAL QUALITY SYSTEM
2. SAFETY
SIA: GUIDELINE ON THE NEED FOR
CARCINOGENICITY STUDIES OF PHARMACEUTICALS
S1B: TESTING FOR CARCINOGENICITY OF
PHARMACEUTICALS
SIC(R2): DOSE SELECTION FOR CARCINOGENICITY
STUDIES OF PHARMACEUTICALS
S2(R1): GUIDANCE ON GENOTOXICITY TESTING AND
DATA INTERPRETATION FOR PHARMACEUTICALS
INTENDED FOR HUMAN USE
S3A: NOTE FOR GUIDANCE ON
TOXICOKINETICS: THE ASSESSMENT OF
SYSTEMIC EXPOSURE IN TOXICITY
STUDIES
S3B: PHARMACOKINETICS:GUIDANCE
FOR REPEATED DOSE TISSUE
DISTRIBUTION STUDIES
S4: DURATION OF CHRONIC TOXICITY
TESTING IN ANIMALS (RODENT AND NON
RODENT TOXICITY TESTING)
S5(R2): DETECTION OF TOXICITY TO
REPRODUCTION FOR MEDICINAL
PRODUCTS & TOXICITY TO MALE
FERTILITY
S6(R1): ADDENDUM TO ICH S6:
PRECLINICAL SAFETY EVALUATION OF
BIOTECHNOLOGY-DERIVED
PHARMACEUTICALS
S6: PRECLINICAL SAFETY EVALUATION
OF BIOTECHNOLOGY DERIVED
PHARMACEUTICALS
S7A SAFETY PHARMACOLOGY STUDIES
FOR HUMAN PHARMACEUTICALS
S7B: THE NON-CLINICAL EVALUATION OF
THE POTENTIAL FOR DELAYED
VENTRICULAR REPOLARIZATION (QT
INTERVAL PROLONGATION) BY HUMAN
PHARMACEUTICALS
S8: IMMUNOTOXICITY STUDIES FOR
HUMAN PHARMACEUTICALS
S9: NONCLINICAL EVALUATION FOR
ANTICANCER PHARMACEUTICALS
3. EFFICACY
E1: THE EXTENT OF POPULATION EXPOSURE TO ASSESS
CLINICAL SAFETY
E2A: CLINICAL SAFETY DATA MANAGEMENT
E2B(R2): MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL
SAFETY DATA MANAGEMENT
E2B(R3): REVISION OF THE ICH GUIDELINE ON CLINICAL
SAFETY DATA MANAGEMENT & DATA ELEMENTS FOR
TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS
E2C(R1): CLINICAL SAFETY DATA MANAGEMENT: PERIODIC
SAFETY UPDATE REPORTS FOR MARKETED DRUGS
E2D: POST-APPROVAL SAFETY DATA MANAGEMENT:
DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING
E2E: PHARMACOVIGILANCE PLANNING
E2F: DEVELOPMENT SAFETY UPDATE REPORT
E3: STRUCTURE AND CONTENT OF CLINICAL
STUDY REPORTS
E4: DOSE-RESPONSE INFORMATION TO SUPPORT
DRUG REGISTRATION
E5(R1): ETHNIC FACTORS IN THE ACCEPTABILITY
OF FOREIGN CLINICAL DATA
E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE
E7: STUDIES IN SUPPORT OF SPECIAL
POPULATIONS:GERIATRICS
E8: GENERAL CONSIDERATIONS FOR CLINICAL TRIALS
E9: STATISTICAL PRINCIPLES FOR CLINICAL TRIALS
E10: CHOICE OF CONTROL GROUP AND RELATED ISSUES IN
CLINICAL TRIALS
E11: CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE
PEDIATRIC POPULATION
E12: PRINCIPLES FOR CLINICAL EVALUATION OF NEW
ANTIHYPERTENSIVE DRUGS
E14: THE CLINICAL EVALUATION OF QT/QTC INTERVAL
PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-
ANTIARRHYTHMIC DRUGS
E15: DEFINITIONS FOR GENOMIC BIOMARKERS,
PHARMACOGENOMICS PHARMACOGENETICS, GENOMIC DATA AND
SAMPLE CODING CATEGORIES
E16: GENOMIC BIOMARKERS RELATED TO DRUG RESPONSE:
4. MULTIDISCIPLINARY
M1- MedDRA: Medical Terminology
M2-ESTRI: Electronic Standards for the Transfer of Regulatory
Information
M3- (R2): Nonclinical Safety Studies for the Conduct of Human
Clinical Trials and Marketing Authorization for Pharmaceuticals
M4-CTD: The Common Technical Document
M5 Data Elements and Standards for Drug Dictionaries
THANK YOU

Más contenido relacionado

La actualidad más candente

European medicines agency
European medicines agencyEuropean medicines agency
European medicines agencyVicky Vignesh
 
New drug application
New drug applicationNew drug application
New drug applicationVKEkbote
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaS S N D Balakrishna Ch
 
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...PRAJAKTASAWANT33
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGaurav Sharma
 
Regulatory requirement for europe union
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe unionShresthaPandey1
 
Clinical Trial Protocol.pptx
Clinical Trial Protocol.pptxClinical Trial Protocol.pptx
Clinical Trial Protocol.pptxVenugopal N
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATIONSACHIN C P
 
Basic concepts about regulatory affairs
Basic concepts about regulatory affairsBasic concepts about regulatory affairs
Basic concepts about regulatory affairsRajkumar Koley
 
Pharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of IndiaPharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of IndiaRutujaNale1
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Surendra Singh
 
Cmc and post regulatory
Cmc and post regulatoryCmc and post regulatory
Cmc and post regulatoryDev Jain
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority Rahul Gawande
 

La actualidad más candente (20)

European medicines agency
European medicines agencyEuropean medicines agency
European medicines agency
 
New drug application
New drug applicationNew drug application
New drug application
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in India
 
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...
Non clinical drug development (Investigational Medicinal Product, IMPD) By Pr...
 
Hatch Waxman Act
Hatch Waxman ActHatch Waxman Act
Hatch Waxman Act
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
 
Regulatory requirement for europe union
Regulatory requirement for europe unionRegulatory requirement for europe union
Regulatory requirement for europe union
 
eCTD
eCTDeCTD
eCTD
 
Clinical Trial Protocol.pptx
Clinical Trial Protocol.pptxClinical Trial Protocol.pptx
Clinical Trial Protocol.pptx
 
NEW DRUG APPLICATION
NEW DRUG APPLICATIONNEW DRUG APPLICATION
NEW DRUG APPLICATION
 
Basic concepts about regulatory affairs
Basic concepts about regulatory affairsBasic concepts about regulatory affairs
Basic concepts about regulatory affairs
 
Pharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of IndiaPharmaceutical regulatory authorities of India
Pharmaceutical regulatory authorities of India
 
Nda and Anda
Nda and AndaNda and Anda
Nda and Anda
 
Anda
AndaAnda
Anda
 
INDA/NDA/ANDA
INDA/NDA/ANDAINDA/NDA/ANDA
INDA/NDA/ANDA
 
ICH guidelines
ICH  guidelinesICH  guidelines
ICH guidelines
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)
 
Cmc and post regulatory
Cmc and post regulatoryCmc and post regulatory
Cmc and post regulatory
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority
 

Similar a ICH Guidelines (20)

Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
ICH Guidelines
ICH Guidelines ICH Guidelines
ICH Guidelines
 
overview of ich guidelines
overview of ich guidelines overview of ich guidelines
overview of ich guidelines
 
Ich guidelines ppt
Ich guidelines pptIch guidelines ppt
Ich guidelines ppt
 
ICH Guidelines.ppt by Dr U .Srinivasa
ICH Guidelines.ppt by Dr U .SrinivasaICH Guidelines.ppt by Dr U .Srinivasa
ICH Guidelines.ppt by Dr U .Srinivasa
 
ICH
ICHICH
ICH
 
ICH PPT
ICH PPTICH PPT
ICH PPT
 
ICH_Public_Mtg._Montreal_2017-converted.pptx
ICH_Public_Mtg._Montreal_2017-converted.pptxICH_Public_Mtg._Montreal_2017-converted.pptx
ICH_Public_Mtg._Montreal_2017-converted.pptx
 
ICH GUIDELINES FOR TESTING OF HERBAL DRUGS AYANSH SINGH.pptx
ICH GUIDELINES FOR TESTING OF HERBAL DRUGS AYANSH SINGH.pptxICH GUIDELINES FOR TESTING OF HERBAL DRUGS AYANSH SINGH.pptx
ICH GUIDELINES FOR TESTING OF HERBAL DRUGS AYANSH SINGH.pptx
 
Ich
IchIch
Ich
 
Ich guidelines of pharmaceutical products
Ich guidelines of pharmaceutical productsIch guidelines of pharmaceutical products
Ich guidelines of pharmaceutical products
 
ICH Guidelines.pptx
ICH Guidelines.pptxICH Guidelines.pptx
ICH Guidelines.pptx
 
ICH guideline.pdf
ICH guideline.pdfICH guideline.pdf
ICH guideline.pdf
 
Ich
IchIch
Ich
 
Jignesh ich
Jignesh ichJignesh ich
Jignesh ich
 
ICH guidelines
ICH guidelinesICH guidelines
ICH guidelines
 
Regulatory guidelines for conducting toxicity studies by ich
Regulatory guidelines for conducting toxicity studies by ichRegulatory guidelines for conducting toxicity studies by ich
Regulatory guidelines for conducting toxicity studies by ich
 
ICH AND ICH GUIDELINES
ICH AND ICH GUIDELINESICH AND ICH GUIDELINES
ICH AND ICH GUIDELINES
 
ICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIESICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIES
 
ICH GUIDELINES OF ICH–QSEM detailed.pptx
ICH GUIDELINES OF ICH–QSEM detailed.pptxICH GUIDELINES OF ICH–QSEM detailed.pptx
ICH GUIDELINES OF ICH–QSEM detailed.pptx
 

Último

How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICESayali Powar
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxDr. Santhosh Kumar. N
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 

Último (20)

How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICE
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
M-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptxM-2- General Reactions of amino acids.pptx
M-2- General Reactions of amino acids.pptx
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 

ICH Guidelines

  • 1. A Seminar On ICH GUIDELINES Presented By SAURABH R. SOJITRA M.Pharm. I (Pharmaceutics) Under The Guidance Of Prof. Ms. H. R. HINGLAJIA
  • 3. INTRODUCTION The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration.
  • 4. AIM The International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) was established in 1990 as a joint regulatory/industry project to improve, through harmonisation, the efficiency of the process for developing and registering new medicinal products in Europe, Japan and the United States, in order to make these products available to patients with a minimum of delay. The six parties to ICH represent the regulatory bodies and research based industry in the three regions, Europe, Japan and the USA, where the vast majority of new medicines are currently developed.
  • 5. ICH PARTIES European Commission European Union (EU) European Federation of Pharmaceutical Industries and Associations (EFPIA) Ministry of Health, Labour and Welfare, Japan (MHLW) Japan Pharmaceutical Manufacturers Association (JPMA) US Food and Drug Administration (FDA) Pharmaceutical Research and Manufacturers of America (PhRMA)
  • 6. OBJECTIVES More economical use of human, animal, and material resources Elimination of unnecessary delay in the global development & availability of new medicines. Maintaining safeguards on Quality, safety, efficacy and regulatory obligations to protect public health.
  • 7. TOPIC OF ICH Four Broad Categories - QSEM Quality (Q): those relating to chemical and pharmaceutical Quality Assurance (Stability Testing, Impurity Testing, etc.) Safety (S): those relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.) Efficacy (E): those relating to clinical studies in human subject (Dose Response Studies, Good Clinical Practices, etc.) Multidisciplinary (M): cross-cutting Topics which do not fit uniquely into one of the above categories (MedDRA, ESTRI, M3, CTD, M5)
  • 8. OVERVIEW OF ICH 1. QUALITY Q1A (R2): STABILITY TESTING OF NEW DRUGS AND PRODUCTS QIB: PHOTOSTABILITY TESTING Q1C: STABILITY TESTING OF NEW DOSAGE FORMS Q1D: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS.
  • 9. Q1E: EVALUATION OF STABILITY DATA QIF: STABILITY DATA PACKAGE FOR REGISTRATION IN CLIMATIC ZONES III AND IV Q2A: DEFINITIONS AND TERMINOLOGY: ANALYTICAL VALIDATION Q2B: METHODOLOGY 03A(R2) IMPURITIES IN NEW DRUG SUBSTANCES 03B(R2): IMPURITIES IN NEW DRUG PRODUCT 03C(R3) IMPURITIES GUIDELINES FOR RESIDUAL SOLVENTS
  • 10. Q4: PHARMACOPOEIA Q4A: PHARMACOPOEIAL HARMONIZATION Q5A: VIRAL SAFETY EVALUATION Q5B: GENETIC STABILITY Q5C: STABILITY OF BIOTECHNOLOGY PRODUCTS Q5D: CELL SUBSTRATES
  • 11. Q6A: SPECIFICATIONS, TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND PRODUCTS Q6B : SPECIFICATIONS TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/ BIOLOGICAL PRODUCTS Q7A: GMP FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q8: PHARMACEUTICAL DEVELOPMENT Q9: QUALITY RISK MANAGEMENT Q10: PHARMACEUTICAL QUALITY SYSTEM
  • 12. 2. SAFETY SIA: GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS S1B: TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS SIC(R2): DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS S2(R1): GUIDANCE ON GENOTOXICITY TESTING AND DATA INTERPRETATION FOR PHARMACEUTICALS INTENDED FOR HUMAN USE
  • 13. S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3B: PHARMACOKINETICS:GUIDANCE FOR REPEATED DOSE TISSUE DISTRIBUTION STUDIES S4: DURATION OF CHRONIC TOXICITY TESTING IN ANIMALS (RODENT AND NON RODENT TOXICITY TESTING)
  • 14. S5(R2): DETECTION OF TOXICITY TO REPRODUCTION FOR MEDICINAL PRODUCTS & TOXICITY TO MALE FERTILITY S6(R1): ADDENDUM TO ICH S6: PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS S6: PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY DERIVED PHARMACEUTICALS
  • 15. S7A SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7B: THE NON-CLINICAL EVALUATION OF THE POTENTIAL FOR DELAYED VENTRICULAR REPOLARIZATION (QT INTERVAL PROLONGATION) BY HUMAN PHARMACEUTICALS S8: IMMUNOTOXICITY STUDIES FOR HUMAN PHARMACEUTICALS S9: NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
  • 16. 3. EFFICACY E1: THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL SAFETY E2A: CLINICAL SAFETY DATA MANAGEMENT E2B(R2): MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT E2B(R3): REVISION OF THE ICH GUIDELINE ON CLINICAL SAFETY DATA MANAGEMENT & DATA ELEMENTS FOR TRANSMISSION OF INDIVIDUAL CASE SAFETY REPORTS E2C(R1): CLINICAL SAFETY DATA MANAGEMENT: PERIODIC SAFETY UPDATE REPORTS FOR MARKETED DRUGS E2D: POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING
  • 17. E2E: PHARMACOVIGILANCE PLANNING E2F: DEVELOPMENT SAFETY UPDATE REPORT E3: STRUCTURE AND CONTENT OF CLINICAL STUDY REPORTS E4: DOSE-RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION E5(R1): ETHNIC FACTORS IN THE ACCEPTABILITY OF FOREIGN CLINICAL DATA E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E7: STUDIES IN SUPPORT OF SPECIAL POPULATIONS:GERIATRICS
  • 18. E8: GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E9: STATISTICAL PRINCIPLES FOR CLINICAL TRIALS E10: CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E11: CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION E12: PRINCIPLES FOR CLINICAL EVALUATION OF NEW ANTIHYPERTENSIVE DRUGS E14: THE CLINICAL EVALUATION OF QT/QTC INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON- ANTIARRHYTHMIC DRUGS E15: DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES E16: GENOMIC BIOMARKERS RELATED TO DRUG RESPONSE:
  • 19. 4. MULTIDISCIPLINARY M1- MedDRA: Medical Terminology M2-ESTRI: Electronic Standards for the Transfer of Regulatory Information M3- (R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M4-CTD: The Common Technical Document M5 Data Elements and Standards for Drug Dictionaries